Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan

European Journal of Heart Failure

Volumn 2, Issue 2, 2000, Pages 183-187

  Gremmler, B ^a   Kunert, M ^a   Schleiting, H ^a   Ulbricht, L J ^b  

^a Marien Hospital Bottrop gGmbH   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

ACE inhibitors; Chronic heart failure; Eprosartan; Norepinephrine; Selective angiotensin II AT1 receptor antagonist

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC NERVE;

ACRYLATES; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIAC OUTPUT; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, ANGIOTENSIN; THIOPHENES; VENTRICULAR FUNCTION, LEFT;

EID: 0034083750     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(00)00060-X     Document Type: Article

References (24)

1. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 316:1987;1429-1435.
2. Erdmann E. Treatment of chronic heart failure with ACE-inhibitors. Gerlach E., Kramer H.J., Kübler W. Z Kardiol: ACE-Hemmung bei Gefäß-und Herzerkrankungen. 83(Suppl 4):1994;75-79.
3. Hopf R. Prognoseverbesserung mit ACE-Hemmern bei kardialer Dysfunktion: Neue Erkenntnisse durch die AIRE-Studie. 1993;Medikon, München.
4. Huber K., Pachinger O., Pichler M., Klein W. Pathophysiologic mechanisms of the renin-angiotensin system and the pharmacological influence of ACE-inhibitors or angiotensin II-Type 1-receptor antagonists in cardio-vascular disease. Z Kardiol. 86:1997;239-250.
5. Linz W., Wiemer G., Gohlke P., Unger T., Schölkens B.A. Cardioprotective effects by ramipril after ischemia and reperfusion in experimental studies. Gerlach E., Krämer H.J., Kübler W. Z Kardiol: ACE-Hemmung bei Gefäß-und Herzerkrankungen. 83(Suppl 4):1994;53-56.
6. Pfeffer M.A., Braunwald E., Moye L. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 327:1992;669-677.
7. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventrikular ejection fractions. N Engl J Med. 327:1992;685-689.
8. Bönner G. Bedeutung der Kinine für die Wirkung der ACE-Hemmer. Dominiak P., Bönner G. ACE-Hemmer in Klinik und Praxis. 1995;37-54 Springer, Berlin.
9. Dendorfer A., Simon M., Dominiak P. Heart affecting hormones: bradykinin. Z Kardiol. 85(Suppl 6):1996;211-218.
10. Dominiak P., Dendorfer A. Pharmakologie und klinische Pharmakologie der AT1-Rezeptorantagonisten. Dominiak P., Unger Th. AT1-Rezeptorantagonisten Angiotensin II. 1997;41-73 Steinkopff, Darmstadt.
11. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 153:1993;937-942.
12. Schieffer B., Drexler H. Pathophysiologie der chronischen Herzinsuffizienz. Dominiak P., Unger Th. AT1-Rezeptorantagonisten Angiotensin II. 1997;129-137 Steinkopff, Darmstadt.
13. Dzau V.J., Sasamura H., Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens. 11(Suppl 3):1993;13-18.
14. Griendling K.K., Lassegue B., Alexander R.W. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol. 36:1996;281-306.
15. Regitz-Zagrosek V., Neuß M., Warnecke C., Holzmeister J., Hildebrand A.G., Fleck E. Angiotensin receptors - organ- and subtype-specific regulation in cardio-vascular disease and with modulation of the renin-angiotensin system. Z Kardiol. 84(Suppl 4):1995;61-69.
16. Timmermans P., Wong P., Chiu A. et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 15(2):1993;205-251.
17. Ohlstein E., Brooks D., Feuerstein G., Ruffolo R. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, Eprosartan, but not by Losartan, Valsartan or Irbesartan: possible relationship to differences in pre-junctional angiotensin II receptor blockade. Pharmacology. 55:1997;244-252.
18. Packer M. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. J Am Coll Cardiol. 20:1992;248-254.
19. Packer M., Bristow M.R., Cohn J.N. et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
20. Pizzulli L., Lüderitz B. Sekundärprävention der koronaren Herzkrankheit-Kardiol. Aspekte Dt Ärzteblatt. 95:1998;A1732-A1738.
21. Siegmund M., Hanrath P. Beta-blockers in chronic heart failure. Z Kardiol. 84:1995;820-826.
22. Knapp E. Impedance cardiography. Wien Klin Wschr. 88(Suppl 58):1976;2-15.
23. Horstmann E. Impedance cardiography during exercise for the assessment of left ventricular function. Z Kardiol. 73:1984;374-379.
24. Löllgen H. Kardiopulmonale Funktionsdiagnostik Edition. 1983;CIBA, Wehr/Baden.